Shijiazhuang Yiling Pharmaceutical Co Ltd SZSE:002603:
SAYS SUBSIDIARY RECEIVED NATIONAL MEDICAL PRODUCTS ADMINISTRATION'S APPROVAL FOR IRBESARTAN
Shijiazhuang Yiling Pharmaceutical Says Subsidiary's Irbesartan Approved
Earlier from Shijiazhuang Yiling Pharmaceutical Co., Ltd. Class A
- Shijiazhuang Yiling Pharmaceutical: Net profit rose 277.56% to ¥1.29 billion on 20.24% revenue growth, with robust cash flow
- Shijiazhuang Yiling Pharmaceutical Sees 2025 Net Profit 1.2-1.3 Billion Yuan
- Shijiazhuang Yiling Pharmaceutical Co: Net profit soared 80.33% to ¥1.00 billion despite a 7.82% revenue decline
- Yiling Pharmaceutical Q3 Net Profit Up 1264.6% Y/Y